No Data
No Data
Hemostemix Closed Private Placement
Hemostemix Inc. (HEM.V) has closed its private placement of $320,125, from the sale of 2.66 million units priced at $0.12 each. Each unit consisted of one common share and one half of one common shar
Hemostemix Offers up to 500 6% Convertible Debentures, Convertible Into an ACP-01 Therapeutic Production Slot That Is Subject to Compassionate Exemption From Regulatory Approval
Calgary, Alberta--(Newsfile Corp. - March 7, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("HEM" or the "Company") is pleased to announce it is selling up to 500 five-year 6% unse
Hemostemix Inc. Is Maintained at Buy by Fundamental Research
Hemostemix Inc. Is Maintained at Buy by Fundamental Research
Thomas Smeenk Sells 300,000 Shares of Hemostemix Inc. (CVE:HEM) Stock
Hemostemix Inc. (CVE:HEM – Get Rating) Director Thomas Smeenk sold 300,000 shares of the business's stock in a transaction on Monday, April 18th. The shares were sold at an average price of C$0.31, f
Hemostemix Appoints Chief Medical Officer
02:38 PM EDT, 10/14/2021 (MT Newswires) -- Hemostemix Inc. (HEM.V) has appointed Dr. Fraser C. Henderson Sr., MD, as its Chief Medical Officer. Dr. Henderson is a neurological surgeon with extensive